B Cell News and Research

RSS

New clues to molecular action of Alzheimer's drug memantine

Alzheimer's disease destroys brain cells and their connections (called synapses), causing memory loss and other cognitive problems that disrupt work, hobbies and daily life. Symptoms can be alleviated, in part, by the drug memantine (marketed in the United States as Namenda), which is currently FDA-approved to treat moderate-to-severe Alzheimer's disease and was, in part, developed by Stuart A. Lipton, M.D., Ph.D., Director of the Del E. Web Center for Neuroscience, Aging and Stem Cell Research at Sanford-Burnham Medical Research Institute (Sanford-Burnham).

19 Aug 2010

U-M research results show potential for discovering new avenues for anti-aging drugs

A team of University of Michigan scientists has found that suppressing a newly discovered gene lengthens the lifespan of roundworms. Scientists who study aging have long known that significantly restricting food intake makes animals live longer. But the goal is to find less drastic ways to achieve the same effect in humans someday. The U-M results offer promising early evidence that scientists may succeed at finding targets for drugs that someday could allow people to live longer, healthier lives.

19 Aug 2010

Cluster-coated implant strengthens attachment of joint-replacement implant with bone

Researchers have developed an improved coating technique that could strengthen the connection between titanium joint-replacement implants and a patients' own bone. The stronger connection created by manipulating signals the body's own cells use to encourage growth could allow the implants to last longer.

19 Aug 2010

TOPEX announces sale of skin cancer business operations to SENSUS Healthcare

TOPEX, Inc. announces the sale of its skin cancer business operations to SENSUS Healthcare, LLC for its low energy SRT 100 superficial radiotherapy treatment system. Since TOPEX received FDA approval during 2007, many systems have been operating worldwide at hospital radiation oncology centers, dermatology and veterinary oncology practices for the treatment of skin cancer.

19 Aug 2010

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

ImmunoGen, Inc., a biotechnology company that develops antibody-based targeted anticancer products, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lorvotuzumab mertansine (formerly IMGN901) product candidate when used for the treatment of small-cell lung cancer (SCLC).

19 Aug 2010

Beltone Electronics launches new generation of wireless hearing instruments

Chicago-based Beltone Electronics recently announced the introduction of the Beltone True™, a new generation of virtually invisible hearing instruments that wirelessly receive sound directly from TV, cell/home phone, stereo, PC, iPod or any audio device via a 2.4 GHz signal.

18 Aug 2010

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has locked the database of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON™ (OX1).

18 Aug 2010

Holzer Consolidated Health System deploys CareTech Solutions Service Desk

CareTech Solutions, an information technology and Web products and services provider for more than 150 U.S. hospitals, announced today, that Holzer Consolidated Health System in Gallipolis, Ohio, selected the company's 24/7 Service Desk and Infrastructure Performance Monitoring solution for its six-facility integrated delivery network.

18 Aug 2010

Point Loma Nazarene University accepts applications for Kyoto Prize Journalism Fellowship

Point Loma Nazarene University is now accepting applications for its Kyoto Prize Journalism Fellowship, a unique learning opportunity for a journalist who has worked to attain a level of excellence in his or her field and hopes to further integrity in the sciences and arts. The selected journalist will attend the 26th annual Kyoto Prize presentation ceremony and will interact with the latest Kyoto Prize laureates in Kyoto, Japan, November 7-14, 2010.

18 Aug 2010

Regenicin acquires worldwide exclusive license to know-how technology

Regenicin, Inc., a development stage biotechnology company, announced today that it has completed an initial $3.25 million funding in conjunction with its acquisition of a worldwide exclusive license to know-how technology controlled by Lonza Walkersville ("Lonza Agreement").

18 Aug 2010

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

18 Aug 2010

XOMA sells royalty interest in CIMZIA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced today that it has sold its royalty interest in CIMZIA® (certolizumab pegol) marketed by UCB S.A. for $4 million to an undisclosed buyer. The manufacture of CIMZIA is covered by a license to XOMA's Bacterial Cell Expression technology.

18 Aug 2010

FDA grants orphan drug designation to NephRx's lead product NX001

NephRx Corporation today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product NX001 for the prevention of delayed graft function in renal transplant recipients. NX001 is a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure.

18 Aug 2010

Toshiba America Medical Systems/RSNA issues grant to three researchers

The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation awarded 2010 Toshiba America Medical Systems/RSNA grants to Kenneth S. Lee, M.D., Nitin Ohri, M.D., and Ben Paxton, M.D. The grants are made possible by Toshiba's support of the RSNA R&E Foundation.

18 Aug 2010

Xcelligence System provides real-time detection of neuronal cell death

Time course analyses of neuronal cell death and its underlying mechanisms require laborious experiments and multiple endpoint assays, often involving labelling with irritating compounds and cell disruption. A recent study used the xCELLigence System of Roche to investigate the response of the neuronal-like cell line HT-22 and cultured primary rat cortical neurons to different cell death stimuli and neuroprotectants.

18 Aug 2010

Research shows mutation in Prox1 gene may lead to memory, learning problems

St. Jude Children's Research Hospital investigators showed a gene named Prox1 is a key player in normal development of a brain structure crucial for learning and memory and remains active throughout life, nurturing the cells vital for making new memories.This study focused on a small region of the hippocampus known as the dentate gyrus, a brain structure needed for memory and learning that is home to the subgranular zone where the neural stem cells destined to become granule cells are housed. The dentate gyrus is one of two regions of the adult brain where neural stem cells continue to produce the precursor cells that ultimately differentiate into neurons.

18 Aug 2010

Advanced Cell Technology to obtain patent for cellular reprogramming, generation of iPS cells

Advanced Cell Technology, Inc. announced today that it is positioned to obtain significant patents relating to cellular reprogramming and the generation of induced pluripotent stem (iPS) cells. iPS cells are similar to embryonic stem (ES) cells, except they are generated from adult cells such as skin using certain reprogramming factors, without the controversial use of embryos. Although human iPS cells were first produced in 2007, ACT has been working on inducing pluripotency, with positive results, for more than a decade. The Company's efforts go back to the 1990s, providing (through existing patent filings and continuations) some of the earliest priority dates in the field.

18 Aug 2010

Mature stem cell research development hinges on quality of science peer review

Are there too many stem cell research journals? This question has been posed by Drs. Paul Sanberg and Cesar Borlongan of the Department of Neurosurgery and Brain Repair at the University of South Florida. Their article appears in the current issue of Stem Cell Reviews and Reports.Both Sanberg and Borlongan are concerned about the quality of the science being published in the proliferating stem cell journals.

18 Aug 2010

Researcher unveils unique stem cell partnership that can lead to advances in regenerative medicine

A study led by a researcher at Albert Einstein College of Medicine of Yeshiva University has revealed a unique "partnership" between two types of bone marrow stem cells, which could lead to advances in regenerative medicine. The aim of regenerative medicine is to enable the body to repair, replace, restore or regenerate damaged or diseased cells, tissues and organs.

18 Aug 2010

UK scientists receive Royal Society awards for cancer research

Two Cancer Research UK scientists were recently awarded prestigious Royal Society Awards, while a number of Cancer Research UK scientists were elected fellows of the Royal Society and the Academy of Medical Sciences.Dr Tomas Lindahl is the recipient of the Royal Society Copley Medal, the world's oldest prize for scientific achievement, and Professor Stephen West is awarded this year's GlaxoSmithKline Prize and Lecture.

18 Aug 2010

B Cell News and Research

New clues to molecular action of Alzheimer's drug memantine

U-M research results show potential for discovering new avenues for anti-aging drugs

Cluster-coated implant strengthens attachment of joint-replacement implant with bone

TOPEX announces sale of skin cancer business operations to SENSUS Healthcare

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

Beltone Electronics launches new generation of wireless hearing instruments

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Holzer Consolidated Health System deploys CareTech Solutions Service Desk

Point Loma Nazarene University accepts applications for Kyoto Prize Journalism Fellowship

Regenicin acquires worldwide exclusive license to know-how technology

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

XOMA sells royalty interest in CIMZIA

FDA grants orphan drug designation to NephRx's lead product NX001

Toshiba America Medical Systems/RSNA issues grant to three researchers

Xcelligence System provides real-time detection of neuronal cell death

Research shows mutation in Prox1 gene may lead to memory, learning problems

Advanced Cell Technology to obtain patent for cellular reprogramming, generation of iPS cells

Mature stem cell research development hinges on quality of science peer review

Researcher unveils unique stem cell partnership that can lead to advances in regenerative medicine

UK scientists receive Royal Society awards for cancer research

Using single B cell screening to boost antibody discovery eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News